Scheduling Endogenous Compounds: The DMT Paradox

“The human body produces DMT. The compound is detectable in blood and urine under normal physiological conditions. Its Schedule I status, 'no accepted medical use, high abuse potential', applies to a compound the body makes.”

Dimethyltryptamine is Schedule I under the US Controlled Substances Act. It has been since the Controlled Substances Act of 1970. Schedule I status means: high potential for abuse, no currently accepted medical use, lack of accepted safety for use under medical supervision.

DMT is also produced by the human body. Barker, McIlhenny and Strassman's 2012 review in Drug Testing and Analysis collected reports of DMT detected in human blood, urine and cerebrospinal fluid, while noting inconsistent methods across studies. It is produced by the lung, retina, and likely other tissues from the amino acid tryptophan through the enzyme aromatic amino acid decarboxylase. The human body manufactures a Schedule I controlled substance as part of normal metabolism.

This creates a legal paradox that has no clean resolution. The Controlled Substances Act schedules chemical compounds; it does not create an exception for endogenous production. The DEA's enforcement focus is on the manufacture, distribution, and possession of DMT in quantities and forms associated with deliberate use, not on the trace amounts found in blood under normal conditions. But the legal distinction between endogenous and exogenous DMT is not written into the law.

The clinical significance: Rick Strassman's hypothesis, that the pineal gland produces elevated DMT during near-death experiences, deep meditation, and REM sleep, has not been confirmed. Strassman documented the hypothesis in DMT: The Spirit Molecule (2001) and has advocated for research to test it. The specific claim about pineal production is disputed; the broader claim about endogenous DMT as a component of altered states remains an active research area.

Colorado's Proposition 122 decriminalized personal possession of DMT alongside psilocybin, ibogaine, and mescaline. The decriminalization applies to the compound as it appears in plant preparations, ayahuasca, for example, and in synthetic form. It does not change the federal Schedule I status. McKenna's account of DMT experiences in True Hallucinations describes encounters with the Schedule I version. Whether they engaged the same system the body uses endogenously is a question the law cannot answer and science has not yet resolved.

Sources

• Strassman et al., Arch. Gen. Psychiatry (1994)
• Barker, McIlhenny & Strassman, Drug Testing and Analysis (2012)
• Colorado Proposition 122 (2022)
• Mindmedicinelaw.com (2026)